Self-Care for Head and Neck Cancer Survivors With Lymphedema and Fibrosis: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Self-Care for Head and Neck Cancer Survivors With Lymphedema and Fibrosis (NCT03030859), a randomized na study. The primary outcome is Feasibility of the LEF-SCP (Self-Care Skill Training Sessions).

2. Clinical Question

The primary outcome was recorded following 3 weeks of LEF-SCP sessions and applied only to Group II and Group III. The posted counts were 20 participants completing training in Group II and 18 in Group III. These counts describe engagement with the training as defined by the registry; they do not by themselves show whether symptoms or function changed.

The trial also included a usual-care-only group, but that group was not part of this primary feasibility outcome. The registry record does not report a primary comparison of the self-care program against usual care for clinical benefit. The question answered by the posted primary result is therefore narrower: whether participants assigned to the two program groups met the specified session-completion threshold, and how similar those completion results were.

3. Trial Design

NCT03030859 is a completed randomized pilot clinical trial sponsored by the University of Pennsylvania. The registry record lists an enrollment of 59 and a parallel-group design. Allocation was randomized, and masking was none. The record lists phase as NA. The trial start date was 2018-06-01, and primary completion was 2022-03-31.

Three groups were described. Group I received usual care only. Group II received usual care plus LEF-SCP. Its program included an MI session over 1 hour and a self-care training session over 1 hour weekly for 3 weeks; participants also reviewed an educational manual and watched self-care videos monthly or more frequently as needed. Group III received usual care plus LEF-SCP and follow-up. The training and educational materials are described similarly, but the available follow-up description ends mid-sentence. Further follow-up procedures are not reported in the registry record.

The primary outcome concerns Group II and Group III only. It counts participants who completed at least 2 out of 3 self-care skill training sessions following 3 weeks of the sessions. The posted results report 20 of 20 participants in Group II and 18 of 19 in Group III meeting that definition. The trial's randomized structure concerns assignment to the three groups; the primary feasibility comparison is between the two groups that received the program.

The registry lists 5 outcome measures, but the secondary results are not reported in the registry record. No additional details about allocation procedures, concealment, trial protocol, or the planned statistical analysis are reported in the registry record. Those omissions limit how much can be concluded about the design beyond the information recorded.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Feasibility of the LEF-SCP (Self-Care Skill Training Sessions), measured over Following 3 weeks of the LEF-SCP sessions.

The primary endpoint is the number of participants who completed the LEF-SCP self-care skill training sessions, with completion defined as attending at least 2 out of 3 sessions. The assessment followed 3 weeks of program sessions and applied only to Group II and Group III. The posted result is 20 participants completing in Group II and 18 in Group III.

This is a feasibility endpoint: it records whether participants reached a prespecified participation threshold for the training. In general, feasibility measures can help describe whether an intervention can be delivered and whether participants engage with its components. Session completion is distinct from a clinical outcome. It does not directly measure the severity of lymphedema or fibrosis, changes in symptoms, function, quality of life, or durability of any change.

The endpoint is useful for describing engagement with the self-care training as recorded in the trial. However, the registry record does not report why participants did or did not complete sessions, whether completion was assessed independently, or how completion related to later clinical outcomes. Nor does the primary endpoint compare the program groups with the usual-care-only group. Its interpretation should remain focused on training completion rather than clinical effectiveness.

7. Results Posted in the Registry

• Group III (Usual Care Plus LEF-SCP Plus Follow-Up): 94.7% (18/19) versus 100.0% (20/20) on control; risk difference -5.3 percentage points (95% CI -15.3 to 4.8), risk ratio 0.95 (0.85–1.05); unadjusted two-proportion z-test p = 0.299.

8. Statistical Interpretation

9. Statistical Methods Explained

What does the risk difference describe?

In general, a risk difference subtracts the event proportion in one group from the event proportion in another. Here the event is completion of the defined self-care training threshold. The posted comparison is Group III relative to Group II, with a risk difference of -0.053. The negative sign indicates that the observed completion proportion was lower in Group III. The estimate is an absolute contrast on the probability scale, not a relative measure.

The underlying posted proportions are 1.0 for Group II and 0.947 for Group III. These correspond to the posted completion counts of 20 out of 20 and 18 out of 19. A proportion at the upper boundary leaves no room for a higher observed value in that group. In general, ceiling effects can make an endpoint less able to distinguish groups when most observed participants meet the criterion.

What does the risk ratio add?

In general, a risk ratio compares one group's event probability with another's by division. The posted risk ratio is 0.947, with a 95% confidence interval from 0.852 to 1.053. A value of 1 represents equal event probabilities under the ratio scale; values on either side represent relative differences in opposite directions. The ratio complements the risk difference, but neither measure changes the endpoint's meaning: both concern completion, not clinical improvement.

Risk differences and risk ratios use different scales. The risk difference expresses an absolute contrast, while the risk ratio expresses a relative contrast. Their values should not be interpreted as interchangeable. Because the event was common in both groups, both summaries describe a high observed level of session completion; they do not prove that the program was effective for health outcomes.

How should the p-value be read?

In general, a p-value measures how incompatible the observed data are with a specified null model, assuming that model and the analysis assumptions apply. The posted p-value is 0.299. It is not the probability that the null hypothesis is true, nor does it measure the probability that the result occurred by chance in a simple everyday sense. It does not establish equivalence. A finding that is not statistically clear can still leave meaningful uncertainty about the possible group difference.

The registry record does not report the exact test or model used to obtain the posted p-value. It also does not report covariate adjustment, a prespecified hypothesis-testing procedure, or a statistical analysis plan. Accordingly, the p-value should be treated as the registry's posted result rather than as evidence about a particular unreported model.

Why does the confidence interval matter?

In general, a confidence interval expresses uncertainty around an estimate under a statistical procedure and its assumptions. The risk-difference interval extends from -0.153 to 0.048. It includes zero, the value corresponding to no absolute group difference, and extends to values on both sides of zero. This means that the observed point estimate is not precise enough to rule out either direction of difference. The interval is not a guarantee that the true effect lies within its limits, and its interpretation depends on the method used to calculate it, which is not reported in the registry record.

What do the planning assumptions mean?

The registry describes a planning illustration based on the observed effect, using a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. It states that the effect to detect is a stated fraction of the observed effect. Such calculations are hypothetical planning exercises, not a measure of observed power and not evidence that the trial had a particular design target. Numerical sample-size outputs for those illustrations are not reported in the registry record. The registry record also does not report its own sample-size justification or the assumptions used for the original trial design.

In general, over-dispersion matters when outcome variability is greater than a model assumes; if ignored, uncertainty may be understated. That concept is not directly relevant to this binary completion count in the way it is for a variable measured on a continuous or count scale. The registry record does not identify a model or variance adjustment, so no such adjustment can be attributed to this analysis.

What can randomization support?

Random assignment is intended, in general, to make groups comparable on average at the point of assignment. It does not guarantee that every measured or unmeasured characteristic is balanced, particularly in a pilot study. Because masking was none, participants and study personnel were not masked according to the registry record. The record does not describe outcome-assessment procedures that would clarify whether knowledge of assignment could have influenced ascertainment of session completion.

10. Confidence Intervals and Precision

The primary comparison has a risk-difference estimate of -0.053 and a 95% confidence interval from -0.153 to 0.048. The interval includes zero and spans values in both directions. This means the observed estimate does not pinpoint the direction or size of a group difference with high precision. The result is compatible with a lower completion proportion in Group III, little or no difference, or a higher completion proportion within the interval's limits.

The risk-ratio estimate is 0.947, with a 95% confidence interval from 0.852 to 1.053. The interval includes 1, the value corresponding to equal group probabilities on the ratio scale. The risk-difference and risk-ratio intervals express uncertainty on different scales, but both leave uncertainty about the group contrast.

Confidence intervals are generally useful because they show a range of estimates compatible with the data and the interval procedure, rather than giving only a single point estimate. They do not give the probability that the true value is inside the particular interval. The registry record does not report how the intervals were calculated, so details of the method and its assumptions are not available.

The small pilot setting and high observed completion values are relevant to precision. The result is based on 20 of 20 completions in Group II and 18 of 19 in Group III. When observed completion is already near the maximum possible, the outcome has limited room to register higher values. The confidence intervals should therefore be considered alongside the counts, not treated as proof that the groups have the same completion experience.

The posted p-value of 0.299 is consistent with uncertainty rather than a statistically clear group difference under the reported comparison. It is not an equivalence test. The registry record does not report a prespecified equivalence margin or a non-inferiority margin, so no formal conclusion of equivalence or non-inferiority is supported.

11. Multiplicity, Missing Data and Analysis Populations

The registry lists 5 outcome measures, while secondary results are not reported in the registry record. The primary feasibility outcome is described, but the other outcome measures and their results cannot be assessed from the posted information. The record does not report which outcomes were prespecified as primary or secondary beyond the outcome identified as primary, nor does it provide a complete analysis plan.

Multiplicity arises in general when several outcomes, time points, groups, or statistical tests are considered. Testing many hypotheses can increase the chance of at least one apparently noteworthy result. Statistical methods can address that issue, but the registry record does not report a multiplicity adjustment or explain how testing across the listed outcomes was handled. The primary comparison should therefore be interpreted as a single posted result, without assuming that it was adjusted for other analyses.

The registry record does not report the analysis population, such as whether results were analyzed according to randomized assignment or only for participants with outcome data. It also does not report missing-data counts, reasons for missingness, imputation procedures, or sensitivity analyses. The posted completion counts give denominators for the two program groups, but the record does not explain how those denominators relate to all randomized participants or whether anyone lacked an assessable outcome.

These omissions matter because analysis choices can affect estimates and their uncertainty. In general, excluding participants with missing outcomes can produce bias if missingness is related to assignment or outcome. No such relationship can be assessed from the registry record. The absence of these details does not show that missing data or multiplicity altered the result; it means the relevant handling and safeguards are not reported in the registry record.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry reports zero serious adverse events, zero other adverse events, and zero deaths in each of the three groups. The reported at-risk counts are 20 for Group I, 20 for Group II, and 19 for Group III for both serious and other adverse events. These are the safety figures recorded for the trial.

A zero count means that no event of the specified category was recorded in the reported group data. It does not establish that the risk of an event is zero, or that the interventions cannot be associated with adverse events. Rare events may not appear in a small trial, and the registry record does not report the safety observation period, event-collection procedures, or additional safety-analysis details.

No serious adverse event terms are listed. The safety results should be read as descriptive counts rather than as a comparative test of safety. The registry record does not report a statistical comparison of adverse-event risks between groups.

13. What the Result Does, and Does Not, Mean

The posted primary result describes completion of the self-care skill training threshold among the two groups assigned to LEF-SCP. Completion was reported for 20 of 20 participants in Group II and 18 of 19 in Group III. The estimated risk difference was -0.053, with a 95% confidence interval from -0.153 to 0.048. The posted p-value was 0.299. These results indicate uncertainty about the size and direction of the completion contrast; they do not establish that the groups are equivalent.

The finding does not show whether LEF-SCP improves lymphedema or fibrosis, changes symptoms, or affects function. The primary endpoint records session attendance against a specified threshold. It is a feasibility measure and not a direct measure of health status. The usual-care-only group was part of the randomized trial, but it was not part of this primary feasibility comparison, and a clinical-outcome comparison with usual care is not reported in the registry record.

The result also cannot establish which program components contributed to completion. Group III included follow-up, but the available description does not give complete details of that component. The registry record does not report participant reasons for noncompletion, measures of self-care behavior after training, or relationships between completion and later outcomes.

More broadly, the record supports a description of the trial's randomized three-group design, the training components, the primary completion counts, and the posted comparison. It does not provide enough information to make claims about treatment efficacy, long-term outcomes, or broader safety. The appropriate interpretation stays close to the feasibility endpoint and recognizes that the statistical comparison is imprecise.

14. Why This Trial Matters Statistically

Feasibility outcomes are statistically distinct from clinical outcomes. This trial's primary measure asks whether participants completed at least 2 out of 3 training sessions, rather than whether lymphedema, fibrosis, symptoms, or function changed. Keeping that distinction clear prevents a participation result from being mistaken for evidence of clinical benefit.

The reported completion counts are high in both program groups, but the comparison remains uncertain. The risk-difference confidence interval crosses zero, and the risk-ratio confidence interval includes 1. These intervals show why the point estimate alone is not enough: the observed contrast does not settle whether completion differed between the groups, or in which direction. A pilot result can be useful for describing participation while still being too imprecise to support a firm comparative conclusion.

The trial's three-group randomized design is also important to interpretation. The primary outcome applies only to the two groups receiving the self-care program, so it does not answer whether the program differs from usual care on this endpoint. Clinical outcome results beyond the primary feasibility measure are not reported in the registry record. Recognizing which comparison was actually posted helps keep conclusions aligned with the evidence available.

Finally, limitations in reporting affect reproducibility. The registry record does not describe the statistical analysis plan, missing-data handling, or multiplicity procedures. These gaps do not invalidate the recorded counts, but they limit assessment of how the analysis was planned and conducted. For biostatisticians and clinical researchers, the result illustrates the importance of separating what a feasibility endpoint directly measures from broader questions that require different outcomes and more complete reporting.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary endpoint is narrow: it records whether participants met a session-completion threshold. It does not measure clinical status, and the registry record does not report whether participants retained or used self-care skills after training. The result therefore cannot be extended to outcomes that were not measured in the posted primary result.

The comparison excludes the usual-care-only group because the endpoint was applicable only to Group II and Group III. The registry record does not report a parallel feasibility result for Group I. As a result, the posted comparison cannot establish how participation in the LEF-SCP groups differed from participation under usual care alone.

The follow-up description for Group III is incomplete in the registry record. Details of the follow-up component and its delivery are therefore not reported in the registry record. This makes it difficult to characterize precisely what distinguished that group beyond the stated addition of follow-up.

The posted comparison has limited precision, and the completion values are near the upper boundary of the endpoint. The registry record does not report the statistical method used to calculate the p-value or confidence intervals, whether estimates were adjusted, or the analysis population. It also does not report missing-data procedures, multiplicity handling, or a full statistical analysis plan.

Finally, the registry lists 5 outcome measures but does not report secondary results. Details about outcome timing beyond the primary assessment, outcome-assessment procedures, and the safety observation period are not reported in the registry record. These reporting limitations constrain interpretation; they should not be mistaken for evidence that the unreported procedures or analyses did or did not occur.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Self-Care for Head and Neck Cancer Survivors With Lymphedema and Fibrosis — NCT03030859.
• Registry record last updated 2024-04-11; status last verified 2024-03.
• Results first posted 2024-04-11.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT03030859 is a completed randomized, unmasked, parallel-group pilot trial sponsored by the University of Pennsylvania. It enrolled 59 participants with head and neck cancer, lymphedema, and fibrosis. The trial compared usual care alone, usual care plus LEF-SCP, and usual care plus LEF-SCP with follow-up.

The primary endpoint assessed completion of at least 2 out of 3 self-care skill training sessions following 3 weeks of sessions. Completion was reported for 20 of 20 participants in Group II and 18 of 19 in Group III. The posted risk difference was -0.053, with a 95% confidence interval from -0.153 to 0.048; p = 0.299.

The primary result concerns training feasibility, not clinical efficacy. Secondary results, analysis details, and missing-data procedures are not reported in the registry record. The registry reports zero serious adverse events, zero other adverse events, and zero deaths in each group.